1,027 results on '"Gattorno M"'
Search Results
302. OR13-004 – Evidence-based clinical classification criteria for periodic fevers
303. PW02-006 - PAPA syndrome clinical spectrum and IL1B release
304. PW03-018 – Efficacy of Anakinra in recurrent pericarditis
305. OR10-006 - Canakinumab in patients with TRAPS
306. P03-021 - Characterization of BM-MSC from osteopetrotic mice
307. PW02-011 - Favorable response to anakinra in aisle patients
308. PW02-007 - The Eurofever registry: 3 years of enrollment
309. PW02-005 - A web registry of genotype-phenotype correlation
310. OR7-006 – Autophagy as a player in inflammation in TRAPS
311. P02-024 - Clinical impact of V198M mutation in NLRP3 gene
312. OR10-005 - Treatment responses in TRAPS: Eurofever/ Eurotraps
313. PW02-021 - SAA1 is the strongest predictor of AA in TRAPS
314. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry
315. FRI0332 Evaluation of treatment in PFAPA syndrome: International cohort and literature review
316. FRI0026 Evidence for interleukin (IL)-1β pathway activation in monocytes from patients with familial mediterranean fever (fmf) and pyogenic sterile arthritis, pyoderma gangrenosum and acne (papa) syndrome
317. AB1201 Diversity in clinical manifestations of autoinflammatory syndromes in a french paediatric rheumatology referral center
318. AB1179 Failure of adalimumab treatment in three patients with papa syndrome
319. OP0107 Clinical features at presentation in a series of 86 patients with genetically confirmed traps and 33 patients with inflammatory symptoms and the r92q variant from the eurofevers/eurotraps registry
320. THU0334 Differences in the features of familial mediterranean fever among patients from europe as compared to those from the eastern mediterranean countries
321. FRI0346 PED-BD, cohort study for paediatric behÇet’s disease: Update 2012 reporting 206 patients
322. SP0156 What’s new in clinical management of autoinflammatory diseases
323. AB1191 Within-patient analysis during anakinra and canakinumab treatment in cryopyrin associated periodic syndrome
324. THU0396 Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome (TRAPS)
325. OP0138 B cell subsets phenotype in autoimmunity with immunodeficiency: Analysis of a large cohort of patients with apeced syndrome
326. OP0175 The eurofever registry for autoinflammatory disease: Update on enrollment after 2 years
327. SAT0466 PED-BD COHORT 2013: Expert Consensus Classification Gives Higher Sensitivity than the International Study Group Criteria to Define Behcet’s Disease in Children
328. The Antiphospholipid Syndrome
329. Brother and sister with different vasculitides
330. Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications
331. CRYOPYRIN ASSOCIATED PERIODIC SYNDROME
332. Unexplained recurrent fever: when is autoinflammation the explanation?
333. Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra
334. PED-BD : cohorte internationale de patients suspects de maladie de Behçet pédiatrique
335. How not to miss autoinflammatory diseases masquerading as urticaria
336. The autoinflammatory diseases
337. Étude de cohorte de la maladie de Behçet Pédiatrique PED-BD : mise à jour 2011
338. Guidelines for the genetic diagnosis of hereditary recurrent fevers
339. A novel mutatioin in the PSTPIP1 gene is associated with an autoinflammatory disease distinct from classical PAPA syndrome
340. Significance of I313V mutation of NLPR3 gene in two pediatric patients
341. Characterization of tonsil infiltration and gene expression profile of innate sensors in PFAPA patients
342. National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
343. Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
344. Therapy of autoinflammatory diseases: results from an international registry
345. B cell subsets phenotype in autoimmunity with immunodeficiency: analysis of a cohort of patients with APECED syndrome
346. Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
347. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
348. Cytokines and inflammatory mediators: 25. Certolizumab Pegol has a Different Profile from the other Anti-TNFS, Including Golimumab, in a Variety of in Vitro Assays
349. Concurrent Oral 1 - Therapy of rheumatic disease: OP4. Effectiveness of Rituximab in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register (BSRBR)
350. Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.